Okay. Around 2013 or 2014, Zhengli Shi identified two new sarbecoviruses called SHC014 and WIV1. She was able to culture WIV1 in cell culture, and they published a paper in Nature on that. And we met at a meeting and we had some discussions. Ultimately, she provided me with the sequences, and we used that, of the spike, going at the spike like a protein. And so we build chimeric viruses. DC.Scheduling@LexitasLegal.com They also, when the paper was finally being written, they had developed what are called pseudotype viruses. These are, in essence, single-hit replicon viruses that are pseudotyped with the spike like a protein, of different coronaviruses. And they showed that WIV1 could infect and use human H2 receptors. But they also showed that SHC014 could not. So when she provided us with those reagents and we recovered viruses, we showed that SHC014, in fact, could use that human receptors for entry. And because they also provided their SHC014 pseudotype data in the paper and provided the virus sequences for this, they were included on the manuscript, and I think their grant was cited. So that's how that worked.